Watch our replay of Enlivex’s FY25 Financial Results Webcast to hear management discuss the company’s outlook, financial performance, and its differentiated dual strategy combining quality longevity therapeutics with a prediction markets treasury model.Key FY2025 Highlights:• Net income of $1.23 billion• Diluted EPS of $25.48• Total treasury and treasury-related derivative assets of $2.31 billion• Shareholders’ equity of $1.93 billion• $30.0 million in cash, cash equivalents, and short-term investments in digital assetsEnlivex is positioning itself as a public market vehicle with exposure to two high-interest themes:• Quality longevity therapeutics, led by Allocetra™ and its focus on inflammatory conditions associated with aging• Prediction markets infrastructure, through treasury exposure tied to the RAIN protocol👉 Enlivex is a client of RedChip. Visit https://www.ENLVinfo.com to learn more and sign up for news alerts.#ENLV #Enlivex #Nasdaq #SmallCapStocks #MicroCapStocks #BiotechStocks #GrowthStocks #StockMarket #InvestorUpdate #Earnings #HealthcareStocks #Longevity #DigitalAssets